AimedBio succeeded in turning a profit in its first year after listing.


On the 6th, AimedBio announced in a provisional disclosure that on a consolidated basis last year it recorded sales of 47.3 billion won and operating profit of 20.6 billion won. Sales surged by about 300% compared to the previous year (11.8 billion won), and operating profit swung to a surplus from a loss of 400 million won a year earlier. In particular, the operating margin reached 44%, demonstrating exceptional profitability.

AimedBio Turns Profitable in First Year After Listing... Operating Profit Reaches 20.6 Billion Won View original image

Given that many bio companies focused on new drug development continue to post losses for an extended period even after going public, it is considered unusual for the company to have achieved such a large operating profit in its first year of listing.



Net profit came in at 4.2 billion won. The company explained that this figure reflects an accounting valuation loss that occurred in the process of converting convertible preferred shares (CPS) and redeemable convertible preferred shares (RCPS) into common shares as the corporate value rose prior to listing. This is a book-entry figure that does not involve any actual cash outflow.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing